ScreenerHero

CRMD CorMedix Inc.

NAS · US · Healthcare · Biotechnology · cormedix.com
7.280USD0.00%Mkt Cap: 567.43M $P/E: 3.55

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an an…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap567.43M USD
Enterprise Value458.20M USD
Revenue (TTM)462.25M USD
Gross Profit275.75M USD
Net Income (TTM)163.06M USD
Revenue/Share5.91 USD
Last Price7.280 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees191
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)3.55
P/E (Forward)20.80
PEG5.21
EV/EBITDA1.75
EV/Revenue0.99
P/S1.23
P/B1.23
EPS (TTM)2.05
EPS (Forward)0.35
52W Range
6.13017% of range13.02
52W High13.02 USD
52W Low6.130 USD
Profitability
Gross Margin88.46%
Oper. Margin42.10%
EBITDA Margin56.80%
Profit Margin52.31%
ROE40.23%
ROA19.74%
Growth
Revenue Growth156.50%
Earnings Growth6.70%
Cash Flow & Leverage
Operating CF175.05M USD
CapEx (TTM)2.26M USD
FCF Margin38.54%
FCF Yield31.39%
Net Debt-109.24M USD
Net Debt/EBITDA-0.42
Balance Sheet
Debt/Equity0.37
Current Ratio2.56
Quick Ratio2.23
Book Value/Sh5.93 USD
Cash/Share3.29 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMar 26, 2019
Splits
Last Split1:5
Split DateMar 26, 2019
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)15.33 USD
Upside (mean)+110.6%
Target Range13.00 USD – 19.00 USD
13.00+110.6% to mean19.00
# Analysts6
Ownership
Shares Out.77.94M
Float65.89M
Insiders7.61%
Institutions57.81%
Short Interest
Short Ratio15.1d
Short % Float21.07%
Short % Out.20.79%
Shares Short16.20M
Short (prev mo.)17.15M
Technical
SMA 507.840 (-7.1%)
SMA 2007.962 (-8.6%)
Beta1.41
S&P 52W Chg16.45%
Avg Vol (30d)968.17K
Avg Vol (10d)879.29K
Technical Indicators
RSI (14)36.7
MACD-0.1817
MACD Signal-0.1159
MACD Hist.-0.0658
BB Upper8.289 USD
BB Middle7.717 USD
BB Lower7.144 USD
BB Width14.84%
ATR (14)0.2724 USD
Vol Ratio (20d)0.94x